IL6 and rheumatoid arthritis: Conventional synthetic disease-modifying antirheumatic drugs such as methotrexate and hydroxychloroquine have been shown to improve metabolic profiles and reduce the risk of type 2 diabetes in RA, while biologics targeting TNF-α and IL-6 signaling may normalize inflammatory–metabolic pathways and even favorably alter body composition [56,57].